{"preliminary_commentary":{"by_channel":{"x_thread":25,"youtube":3,"podcast":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03915951\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"C4221008; PHAROS","nct_id":"NCT03915951","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=c4221008-pharos-nct03915951. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.\n\nPatients will receive the following per 28-day (± 3 days) cycle:\n\n* Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)\n* Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)","label":"Treatment Period","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-10-03","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":98,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"encorafenib","otherNames":[],"type":"DRUG"},{"name":"binimetinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-24","lead_sponsor":"Pfizer","official_title":"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-09-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR)","timeFrame":"From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)"}],"references":[{"citation":"Johnson ML. Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS. J Clin Oncol. 2026 Jun 20;44(18):1748-1749. doi: 10.1200/JCO-26-00311. Epub 2026 Mar 31. No abstract available.","pmid":"41915880","type":"DERIVED"},{"citation":"Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2026 Apr;22(8):873-885. doi: 10.1080/14796694.2026.2645982. Epub 2026 Mar 30.","pmid":"41910021","type":"DERIVED"},{"citation":"Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ. Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Dec 10;43(35):3706-3713. doi: 10.1200/JCO-25-02023. Epub 2025 Oct 19.","pmid":"41109959","type":"DERIVED"},{"citation":"Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal E, Negrao MV, Offin M, Provencio M, Ramalingam SS, Roof L, Sanborn RE, Smit EF, Tsao A, Usari T, Alcasid A, Wilner K, Tonkovyd S, Zhang X, Johnson BE. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. J Thorac Oncol. 2025 Oct;20(10):1538-1547. doi: 10.1016/j.jtho.2025.05.023. Epub 2025 Jun 4.","pmid":"40480428","type":"DERIVED"},{"citation":"Baik C, Cheng ML, Dietrich M, Gray JE, Karim NA. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. Adv Ther. 2024 Jul;41(7):2586-2605. doi: 10.1007/s12325-024-02839-4. Epub 2024 May 2.","pmid":"38698170","type":"DERIVED"},{"citation":"Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 Jul 20;41(21):3700-3711. doi: 10.1200/JCO.23.00774. Epub 2023 Jun 4.","pmid":"37270692","type":"DERIVED"},{"citation":"Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BE. Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncol. 2022 Mar;18(7):781-791. doi: 10.2217/fon-2021-1250. Epub 2021 Dec 17.","pmid":"34918546","type":"DERIVED"}],"start_date":{"date":"2019-06-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03915951"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/c4221008-pharos-nct03915951"}